New drugs are not enough‑drug repositioning in oncology: An update

Int J Oncol. 2020 Mar;56(3):651-684. doi: 10.3892/ijo.2020.4966. Epub 2020 Jan 20.

Abstract

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.

Keywords: drug; repositioning; repurposing; oncology.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Repositioning
  • Humans
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents